INFU InfuSystem Holdings, Inc Insider Trading

Director Paul Gendron purchases 5,000 shares on open market while stock trades well below 52-week highs; second open-market buy in 36 months.

Paul Gendron, a company director, is making a second open-market purchase of shares in InfuSystem, adding to a single prior buy from earlier in the 36-month window. The stock is currently trading well below its 52-week high, having declined significantly over the past month, creating a price environment where repeat insider buying typically occurs. InfuSystem remains profitable with growing revenue, trading at a moderate valuation—the type of fundamentals that might justify director confidence during a pullback. However, the timing of Gendron's prior open-market purchase revealed conflicting results: the stock fell slightly in the near term after that buy but recovered and gained over a longer three-month horizon. The current purchase at lower prices suggests he may be adding to a position he viewed favorably before, though the mixed outcomes from his previous trade mean this is not a pattern of flawless market timing.

INFU's President & CEO Carrie Lachance purchases 3,000 shares in two tranches amid broad insider buying and stock weakness.

Carrie Lachance, INFU's President and CEO, acquired 3,000 shares across two purchases within a three-day window. This activity is part of a broader wave of insider buying at InfuSystem, with three insiders purchasing shares in the same two-week period. The CEO is buying at a time when the stock trades well below its 52-week high and has declined sharply over the past month, suggesting purchases during a pullback. Notably, Lachance has a track record of well-timed buying at this company—her two prior open-market purchases over the past year were followed by material gains, establishing a pattern of buying into weakness that subsequently recovers. The underlying company remains fundamentally sound, posting year-over-year revenue growth and profitability, which provides a foundation for this buying activity. This is Lachance's third and fourth open-market purchase in the 36-month window, indicating a consistent pattern of share acquisition rather than a one-time event.

CFO Barry Steele buys 7,000 shares as stock trades well below 52-week high; repeat buyer with mixed prior timing.

Barry Steele, the company's Executive VP and CFO, is making his fourth open-market purchase in the past three years, adding 7,000 shares while InfuSystem's stock trades roughly one-fifth below its 52-week high and has declined over the past month. The company is profitable with growing revenue, making this a financially healthy backdrop for an insider purchase at a lower price point. However, Steele's prior three purchases at this stock show mixed results: two of them were well-timed and saw the stock rise afterward, but one recent buy in early March saw the stock decline in the following months, suggesting his timing has not been consistently reliable. This current purchase notably comes while the stock is in relative weakness, a pattern often associated with insider confidence, though his recent track record at this ticker warrants watching to see whether this trade proves to be well-timed or repeats the more recent miss.

INFU CFO Barry Steele buys 2,064 shares at $9.16; prior INFU buys both well-timed with 63.7% and 1.3% 90d returns

CFO Barry Steele purchased 2,064 shares at $9.16 on 2026-03-02, expanding his position to 88,000 shares. His timing pattern at InfuSystem is notable: both prior open-market buys at this ticker (2025-05-14 and 2024-05-20) were well-timed, with the more recent purchase yielding a 90d return of 63.7% and the earlier one 1.3%. The current purchase occurs when the stock trades at $9.29, roughly 13.8% below its 52-week high of $10.78 but up 12.5% over the preceding 30 days. Fundamentals show the company generated $36.5M in quarterly revenue with $2.3M net income and a modest P/E of 18.96. The question for investors is whether this buy reflects the insider's demonstrated pattern of well-timed entry points at this specific ticker, or whether prior successful timing is nonpredictive of future outcomes in a market that has already recovered significantly from recent lows.

Director Eichenbaum buys 2,000 INFU shares at $5.18; stock -45.1% from 52-week high, prior buy gained +41.1% over 90 days, cluster of 3 other insider buys in past 14 days.

Director Kenneth D. Eichenbaum purchased 2,000 shares at $5.18, increasing his holdings by 50.0% to 6,000 shares total. The transaction occurs with the stock trading -45.1% from its 52-week high of $9.51, and notably, Eichenbaum's single prior buy at this ticker on 2024-09-23 delivered a 90-day return of +41.1%, suggesting his previous buy was well-timed. Additionally, 3 other insiders have purchased within the past 14 days, forming a cluster buy pattern that extends beyond this director's individual decision. The fundamental backdrop shows net income at $-267.0K (latest quarter) against $34.7M in revenue, with a P/E of 34.80, indicating the stock is expensive relative to near-term profitability despite modest 7.2% annual revenue growth.

Director Ronald T Hundzinski bought 5,000 shares of INFU at $6.09; cluster pattern with 2 other insiders buying within 14 days

Director Hundzinski initiated a position of 5,000 shares at $6.09 on 2025-05-19, spending $30,450.00. The transaction occurs within a cluster pattern where 2 other insiders also purchased within the past 14 days, suggesting aligned interest in the stock at current levels. INFU is trading at $6.10, near the transaction price, after a +24.2% move over the past 30 days but remains -28.7% over 90 days and -35.9% from its 52-week high of $9.51. The company reported $34.7M in latest quarterly revenue with annual growth of +7.2%, though net income was negative at $-267.0K, indicating operational challenges despite top-line growth.

INFU President/COO Lachance buys 3,132 shares across 2 transactions totaling $18,986.66; cluster pattern with 2 other insiders buying within 14 days

Carrie Lachance, President and COO, purchased 3,132 shares in two separate transactions on 2025-05-15 and 2025-05-16 at a blended average price of $6.06, bringing her post-transaction holdings to 190,212 shares. The stock is currently trading at $6.12, -35.6% from its 52-week high of $9.51, while the 30-day change shows +24.6% recovery. The filing reveals a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated insider purchasing activity. Against mixed fundamentals (revenue of $34,716,000.00 with negative net income of -$267,000.00 and P/E of 40.80), the convergence of multiple insider purchases near recent lows warrants investor attention to the company's near-term trajectory and what informed these executives' purchase decisions.

CFO Steele Barry G bought 3,000 shares of INFU at $5.76; stock currently $5.73, down 39.8% from 52-week high of $9.51.

Executive VP and CFO Steele Barry G purchased 3,000 shares at $5.76, bringing holdings to 76,887 shares, a 4.1% increase in his position. The transaction occurred near the lower end of the stock's 52-week trading range ($4.70–$9.51), and the current price of $5.73 is -39.8% below the 52-week high. His prior INFU purchase on 2024-05-20 delivered a +1.3% 90-day return, establishing a pattern of prior trades at this ticker that were well-timed. However, the company is unprofitable (latest quarter net income: $-267,000.00) with modest quarterly revenue ($34,716,000.00) and a high trailing P/E of 38.20, creating a valuation environment where insider buying merit scrutiny relative to fundamental weakness. The 30-day momentum (+14.6%) provides recent price support, but the 90-day decline (-28.4%) signals ongoing pressure.

Director Kenneth D. Eichenbaum bought 4,000 INFU shares at $5.89 on 2024-09-23, opening a new position worth $23.6K

Kenneth D. Eichenbaum, a director, purchased 4,000 shares at $5.89 on 2024-09-23, establishing an initial position in InfuSystem Holdings. The transaction occurred near the lower end of the 52-week range of $5.80–$10.89, approximately 45.3% below the high. InfuSystem reported recent quarterly revenue of $33.7M with net income of $717.0K and annual revenue growth of 14.4%, but the company trades at a P/E of 298.00, indicating either minimal recent profitability relative to price or elevated valuation expectations. The stock has declined 7.4% over the past 30 days and 13.0% over 90 days, suggesting challenging near-term momentum at the time of this insider purchase.